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Rosenstock study and other two RCTs compared Glargine to Determir showed 
Glargine and Determir has not difference in HbA1c control and hypoglycemia rate 
for the patient with type 2 diabetes. Based on the Rosenstock study, cost-minimization 
study was performed. Mean daily detemir dose was higher (0.78 U/kg [0.52 with once 
daily dosing, 1.00 U/kg with twice daily dosing]) than glargine (0.44 IU/kg). Annual 
direct cost was estimated from the perspective of the health insurance in China. The 
time horizon was one year of treatment. The price was referred to Price in 2008. The 
currency is Yuan. The cost of insulin medication (glargine or determir) and consum-
able items (needles, blood glucose test strips) was collected as the direct costs. Univari-
ate sensitivity analysis on resource use and unit costs around base case parameter 
values was performed to test the robustness of the base case results RESULTS: Insulin 
glargine was associated with 40.77% (8949.05RMB per year)cost saving compared 
to insulin determir, for an equivalent level of metabolic control , although the price 
of determir is lower in China. Univariate sensitivity analysis on resource use and prices 
in Determir has been performed and conﬁrmed the robustness of the results in favour 
of insulin glargine in China. The current study ﬁndings are consistent with the direc-
tion and magnitude of cost saving reported in Spain, Hungary, Argentina, Germany 
and UK. CONCLUSIONS: Insulin glargine was cost saving compared to insulin 
determir in China. The information is importance for health care providers who are 
considering the total budget for the type 2 DM patient with basal insulin.
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OBJECTIVES: To determine the cost-effectiveness ratio of adding saxagliptin to 
metformin therapy (SAXA+MET) compared to adding sulfonylureas (SULF+MET), in 
patients with type 2 diabetes mellitus (DM2) who have failed to achieve adequate 
glycemic control with metformin. METHODS: A discrete event simulation model 
(Cardiff Long term cost-utility model) based on UKPDS 68 with a ﬁxed time increase 
was used to simulate disease progression and to obtain an estimate of the treatment’s 
economic and health consequences in DM2 patients. The clinical efﬁcacy parameters 
for saxagliptin were obtained from the literature; drug acquisition costs, adverse 
effects (AEs) and microvascular and macrovascular complications were taken into 
account. Costs were expressed in United States dollars (2009), with an annual 3.5% 
discount. The time horizon was 20 years. RESULTS: A lower number of non-fatal 
events was found for the SAXA+MET-treated group versus the SULF+MET-treated 
group. Additionally, the model predicted a lower number of fatal events due to mac-
rovascular (146 vs. 151) and microvascular (17.7 vs. 17.9) events for the SAXA+MET-
treated group vs. the SULF+MET-treated group. The total cost of the SAXA+MET 
cohort was 14% higher than that of the SULF+MET cohort. Treatment with 
SAXA+MET resulted in a higher number of QALYs (9,392 vs. 9,172) and LYGs 
(20,898 vs. 20,797) than treatment with SULF+MET; the additional cost per QALY 
and LY gained was US$6,691 and US$ 14,656 respectively. CONCLUSIONS: Con-
sidering the GDP per capita in Argentina, results suggest that the addition of saxaglip-
tin to metformin therapy compared to the addition of sulfonylureas would yield 
acceptable cost-effectiveness ratios in DM2 patients in Argentina.
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OBJECTIVES: To assess the impact of pDPN/PHN-related health impairment on 
LOPT in patients treated with chronic pDPN/PHN. METHODS: Using data from 777 
employed adults with ≥3 months of pDPN/PHN and receiving pain medications, the 
effect of pDPN/PHN-related impairment on LOPT was estimated by: 1) single equa-
tion probit models (SEPM) assuming pain severity was exogenous, adjusting for 
respondents’ demographics, depression, anxiety, pain duration, type of pain, social 
isolation (felt alone/didn’t want to go out) and psychological distress (felt older/sleep 
difﬁculties); and 2) seemingly unrelated bivariate probit models (SUBPM), hypothesiz-
ing pain severity was endogenous and considering the same explanatory variables from 
the SEPM as instrumental variables (IVs). Pain severity was measured using a rating 
scale ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”). RESULTS: 
Thirty percent of respondents reported LOPT. Compared to respondents without 
LOPT, respondents with LOPT were younger, male, and had more moderate/severe 
pain (all p < 0.001). Pain severity appears signiﬁcantly related with social isolation 
and psychological distress. Its relationship with LOPT appears only signiﬁcant when 
the latter variables were neglected in the SEPM or when they were used as IVs in the 
SUBPM. Marginal effects indicated that, compared to respondents with pain severity 
< 4, those with pain severity ≥4 were 19.3% more likely to incur LOPT when using 
the SEPM and, 29.5% more likely when using the SUBPM (all p < 0.001). Model 
speciﬁcation tests suggested that pain severity to be truly endogenous and that all IVs 
jointly had sufﬁcient explanatory power (all p < 0.001). CONCLUSIONS: Pain sever-
ity has a signiﬁcant impact on LOPT. The degree of this impact depends on ones’ 
ideas about how this impact is mediated by respondents’ social isolation and psycho-
logical distress. Alternative IVs for adjusting endogeneity bias of pain severity are 
worth exploring.
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OBJECTIVES: The purpose of this study is to consider the extent to which estimates 
of the impact of diabetes on employment status, absenteeism and presenteeism varies 
between China and Japan. METHODS: Data from the 2008 and 2009 National 
Health and Wellness Surveys undertaken in Japan and urban China were used to 
estimate a logistic employment status model and ordered probit regression analyses 
of the determinants of absenteeism and presenteeism for those employed full-time, 
part-time or self employed. Absenteeism was determined by respondents indicating 
time off due to ill health in the past seven days; presenteeism was determined by 
respondents assessing the extent to which workplace productivity was impacted by 
their health status in the same time period. Apart from diabetic status the models 
included demographic and socio-economic characteristics, the Charlson Comorbidity 
Index, together with health risk factors and controls for absenteeism experience and 
diagnosed diabetes. RESULTS: In both China and Japan a diagnosis of diabetes was 
found to have a signiﬁcant (1% level) negative impact on employment status (odds 
ratios 0.540 and 0.796 respectively). The results for absenteeism point once again to 
the signiﬁcant (at 1% level) positive impact of diabetes on higher rates of absenteeism 
with odds ratios of 3.057 for China but only 1.410 respectively for Japan. In the case 
of presenteeism the impact of diabetes is still signiﬁcant (1% level) in the case of China, 
but less so for Japan (odds ratios 2.102 and 1.179 respectively). CONCLUSIONS: 
The presence of diabetes has a signiﬁcant and negative impact on workforce status as 
well as on absenteeism in China and Japan. Both countries show similar impacts, 
although in Japan the impact on presenteeism is less marked.
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OBJECTIVES: The purpose of this study is to consider the extent to which estimates 
of the impact of diabetes on presenteeism can vary between major industrial countries 
and to assess the relative contribution of absenteeism, socio-demographic and health 
risk factors. METHODS: Data from the 2008 National Health and Wellness Survey, 
a national survey of ﬁve EU countries (the UK, France Spain, Germany and Italy) were 
used to estimate an ordered probit regression analysis of the determinants of presentee-
ism for those employed full-time, part-time or self employed. Presenteeism was deter-
mined by respondents assessing the extent to which workplace productivity was 
impacted by their health status on a 10-point scale. The model includes health risk 
factors (BMI, alcohol use, smoking), the Charlson Comorbidity Index (CCI) along 
with controls for absenteeism experience and diagnosed diabetes. RESULTS: Absen-
teeism, the percentage of time lost in the previous seven days, was the dominant factor 
impacting presenteeism for all countries (odds ratios 16.17 Germany to 9.23 Italy). 
With the exception of Spain, obesity and morbid obesity had a positive and signiﬁcant 
impact with odds ratios in the range 1.33 – 1.04 and 2.08 – 1.60 respectively. The 
presence of diabetes was signiﬁcant for all countries with odds ratios ranging from 
1.29 (Italy) to 1.77 ( Spain). Replacing diabetes with the CCI resulted in signiﬁcant 
odds ratios in the range 1.33 (Germany) to 1.17 ( UK). CONCLUSIONS: The presence 
of diabetes has a signiﬁcant and negative impact on workplace presenteeism. The 
impact of diabetes is of a similar order of magnitude to the presence of obesity and 
morbid obesity.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes Studies
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BELIEFS AND EXPECTATIONS ABOUT DIABETES AND MEDICATION 
ADHERENCE IN PERSONS WITH TYPE 2 DIABETES
Iyer N, Thomas J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Associations between type 2 diabetic patients’ beliefs and expectations 
about their illness and medication adherence were determined. METHODS: A cross-
sectional self-administered written survey of type 2 diabetes patients was conducted 
in an outpatient pharmacy, at a primary care clinic afﬁliated with a hospital serving 
an urban population. Study inclusion criteria were being 18 years or older, diagnosed 
with type 2 diabetes at least 6 months prior to the time of the survey, and taking oral 
anti-diabetic medication. Exclusion criteria were use of insulin or not being able to 
read and write in English. The survey included the Brief Illness Perception Question-
naire (B-IPQ) to assess individuals’ illness beliefs and the Morisky 8-item Medication 
Adherence Scale to collect self-reported adherence. Chi-square tests of association and 
Pearson correlation analysis were used to assess whether illness beliefs were associated 
with adherence. RESULTS: Two-hundred and ﬁve completed responses were obtained 
from 354 individuals who satisﬁed inclusion and exclusion criteria, for a response rate 
of 58%. The sample was 50% Caucasian, 50% African-American, 63% female and 
72% had annual household income of less than $25,000. A majority (56%) reported 
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poor adherence to diabetes medications (Morisky adherence score < 6). The propor-
tion of individuals with poor adherence rather than good adherence, was higher 
among individuals with high B-IPQ scores for illness consequences (65%, p < 0.006), 
illness symptoms (67%, p < 0.008), emotional effect of illness (63%, p < 0.012) and 
among those with low B-IPQ scores for illness understanding (76%, p < 0.008). Illness 
beliefs regarding how well treatment can control diabetes (0.23, p < 0.007), concerns 
about diabetes (0.21, p < 0.017) and understanding of the illness (0.20, p < 0.002), 
had positive correlations with medication adherence. CONCLUSIONS: Illness beliefs 
were associated with adherence to diabetes medication and may be useful in assessing 
patients’ potential for adherence problems.
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REVIEW
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OBJECTIVES: Compliance with treatment is a key factor for successful treatment of 
chronic conditions like type 2 diabetes mellitus. Once-daily extended-release glipizide 
(GXL) has been showing more appealing in patient compliance. However, the data 
on comparison of GXL with other oral glucose-lowering drugs concerning compliance 
is limited. We tried to assess the compliance to GXL treatment for type 2 diabetes 
mellitus when compared with immediate-release glipizide(GIR). METHODS: We 
searched Medline, EMBASE, Cochrane Library, and the Chinese Biomedical database 
from their inception to end-Dec. 2009, as well as traced the reference lists. Rand-
omized or non-randomized studies that reported medication compliance/adherence or 
persistence when using GXL versus GIR for treating the type 2 diabetes mellitus were 
included. Four reviewers judged trial eligibility and extracted data independently. We 
pooled trial data using the random-effect model and explored heterogeneity by using 
pre-speciﬁed variables. RESULTS: A total of 9 published studies (n = 13 512) were 
included. GXL resulted in a 7% increase in compliance when compared with GIR 
(RD = 0.07, 95%CI = 0.06 to 0.08). The subgroup analyses showed that GXL 
increased patient compliance by 7% when compared with GIR in 4 retrospective 
database analyses (n = 13 250, RD = 0.07, 95%CI = 0.05 to 0.10) and showed no 
difference in 5 randomized trials (n = 262, RD = 0.01, 95%CI = −0.03 to 0.05). There 
was no signiﬁcant difference in patient compliance between ﬁxed-dose GXL and GIR 
(RD = 0.05, 95%CI = −0.01 to 0.11); however, the titrated-dose GXL signiﬁcantly 
increased patient compliance by 6% (RD = 0.06, 95%CI = 0.03 to 0.09). When 
compared to GIR, GXL in long-term treatments (equal to or more than 1 year) 
increased patient compliance by 7% (RD = 0.07, 95%CI = 0.05 to 0.08), while no 
signiﬁcant difference in short-term treatments (less than 1 year). CONCLUSIONS: 
When compared to immediate-release glipizide, extended-release glipizide could 
increase long-term patient compliance in retrospective database studies, while the 
increase in the short-term compliance to GXL was not observed.
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OBJECTIVES: The aim of this study was to measure adherence and persistence of 
oral hypoglycemic agents among Type II Diabetes patients and to examine differences 
in adherence and persistence by type of oral hypoglycemic agent (OHA) and demo-
graphic characteristics. METHODS: A retrospective analysis was conducted using 
Mississippi Medicaid claims data for 2002 through 2004. After a 6-month wash-out 
period, patients beginning OHA monotherapy were classiﬁed as taking sulfonylurea, 
metformin hydrochloride, thiazolidinediones (TZDs) or other. Patients were observed 
until they had a lapse in Medicaid coverage or discontinued mono therapy on the 
original OHA. A reﬁll gap > 2*day supply was considered to be discontinuation of 
therapy. Persistence was measured as percent of patients remaining on therapy at the 
end of each month. Adherence rates, proportion of days covered (PDC), were com-
puted for each 90 day period that patients remained on therapy after the ﬁrst ﬁll date. 
RESULTS: A total of 6,206 diabetic patients > 18 years of age were included with 
49% on sulfonylurea, 29% on metformin and 16% on TZDs. After 6 months persist-
ence was signiﬁcantly higher for sulfonylurea and TZD (46% and 45% at 12 months) 
compared to metformin (42%). Persistence dropped to around 25% by 18 months. 
Mean adherence rates for Q1 (ﬁrst 90-day period) were 80% for metformin, 82% for 
sulfonylurea, and 85% for TZD. Mean adherence rates dropped in Q2 to 68% for 
metformin, 71% for sulfonylurea, and 72% for TZD and remained relatively stable 
for patients remaining on therapy for up to 2 years. CONCLUSIONS: The rapid drop 
in persistency for monotherapy OHAs is not surprising since diabetic regimens are 
frequently modiﬁed. Although average adherence rates for all types of monotherapy 
OHAs remained steady after Q2, the average rate was below 80%. These results 
indicate that new OHA patients need extra counseling about the importance of 
adherence.
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OBJECTIVES: Oral antidiabetics(OAD) have comparable safety and efﬁcacy in ﬁxed-
dose combination therapies(FDCT) and loose-pill combination therapies(LPCT) for 
patients with Diabetes Mellitus Type II(T2DM). To evaluate FDCT outcomes besides 
safety and efﬁcacy a systematic review was conducted. METHODS: Searches of 
Medline/Embase databases from 1998–2009 used predeﬁned search terms: “ﬁxed-dose 
combination”, “loose-dose combination” and “diabetes”. Additionally, we reviewed 
abstracts from ISPOR, EASD and ADA meetings. T2DM studies were included if they 
reported adherence, patient reported outcomes(PRO), costs, resource use or cost-
effectiveness. RESULTS: Seventeen studies met the search criteria. Seven studies 
reported adherence. Adherence was 10–13% higher for FDCT than LPCT in patients 
starting combination therapy(two studies). Adherence decreased 1.5% and 10.0% 
when switching from monotherapy to combination therapy for FDCT and LPCT, 
respectively(one study, P < 0.001). Three studies report adherence when switching 
from LPCT to FDCT versus remaining on LPCT. Switching to FDCT increased adher-
ence 3.5%–12.4%, while remaining on LPCT changed adherence −1.5% to 5.0%(P 
< 0.005). For patients newly initiating OAD medication, one study found no adherence 
advantage for FDCT, compared with monotherapy or LPCT. Five randomized con-
trolled trials(RCTs) reported treatment satisfaction. Four publications found patients 
preferred FDCT using the Diabetes Treatment Satisfaction Questionnaire(DTSQ). One 
publication found improved satisfaction for one DTSQ subscale only. Five abstracts 
reported economic outcomes. Two abstracts determined patients on FDCT use fewer 
health care resources and decreased direct health care costs by $169 and $255 patient 
per month than LPCT(P < 0.05). Two cost effectiveness models determined clinical 
beneﬁts from clinical trials translate into cost savings and increased life expectancy. 
One budget impact model reported minimal budget impact. CONCLUSIONS: Com-
pared to T2DM patients on LPCT, FDCT users may have better adherence, improved 
satisfaction, and lower direct medical costs. Overall, data for economic implications 
are limited. Further studies are warranted to further deﬁne potential beneﬁt of FDCT 
in T2DM, a prevalent and costly disease.
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MEDICATION POSSESSION RATIOS IN ADULT WORKING AGE 
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OBJECTIVES: The objective of this research project was to evaluate the effect of 
health insurance plan type on anti-diabetic medication adherence as measured by 
medication possession ratios (MPR > 0.80: good MPR) for oral medications. 
METHODS: The data source for this research project was the 2000–2001 MarketScan 
dataset, which is comprised of administrative claims data for over 2.5 million privately 
insured individuals in the United States. MPR was deﬁned as the sum of days 
supply each anti-diabetic medication divided by the number of days between the ﬁrst 
and last prescription ﬁll dates plus the number of days for the last reﬁll. RESULTS: 
The odds of having a good MPR for oral anti-diabetic medications were evaluated 
using multiple logistic regression models controlled for insurance plan type plus 
demographic and clinical characteristics of the target patient population. A propensity 
score analysis was done using a stratiﬁcation approach to further control for selection 
bias. The proportion of patients with MPR ≥80% was 68.2%. CONCLUSIONS: 
Patients in capitated plans were more likely to have good MPR compared to FFS, PPO 
and POS plan types (odds ratios: 0.75, p < 0.001; 0.81, p < 0.001; 0.81, p < 0.001, 
respectively). This relationship remained in all quintiles of the propensity score 
analysis.
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STATES
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OBJECTIVES: 1. To determine the pattern of adherence to statins among the diabetes 
patients at a self-insured university. 2. To determine the effect of independent variables 
[age, gender, co-payment, and campus location (main campus/health science campus)] 
on adherence to statins. METHODS: Pharmacy claims data was used to identify 
patients using both diabetes and statin drugs during the study period between January 
1, 2006 and June 2, 2008. Adherence to statins was calculated at regular observation 
periods using Medication possession ratio (MPR). Patients with MPR ≥ 80% were 
considered adherent. Patients with MPR < 80% were considered non-adherent. Logis-
tic regression was used to study the effect of independent variables on adherence to 
statins. RESULTS: Two hundred and ninety-ﬁve patients were included in the study. 
The mean age of the patients was 55.09 ± 9.30 years. The mean MPR of statins was 
0.76, 0.70, and 0.68 in the 6, 12, and 24 months observation periods respectively. 
During the ﬁrst six months, about 58% of patients were adherent to statins with MPR 
≥ 0.80. About 51% and 48% of patients were adherent to statins during the 12 and 
24 months observation periods. Age was signiﬁcantly positively associated with adher-
ence to statins (Odds ratio, 1.04; 95% CI, 1.01–1.07). Males were 48.3% more likely 
